— Know what they know.
Not Investment Advice

AMPH NASDAQ

Amphastar Pharmaceuticals, Inc.
1W: -2.6% 1M: -2.5% 3M: +26.4% YTD: -3.7% 1Y: +3.0% 3Y: -43.2% 5Y: +33.8%
$25.57
+0.10 (+0.39%)
After Hours: $24.50 (-1.07, -4.18%)
Weekly Expected Move ±4.8%
$23 $24 $25 $26 $28
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 46 · $1.1B mcap · 31M float · 1.54% daily turnover · Short 72% of daily vol
Credit Risk of going bust: higher than 70% of companies Debt: 38.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.35 (down 95%), Amphastar Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $688.3M against a stock market value of $1.08B.
Distance to default 3.43 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $307.3M (short-term plus half of long-term), stock volatility 53.9%; Altman Z 2.15. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Watch 25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.1B
52W Range16.65-29.52
Volume225,240
Avg Volume481,799
Beta0.90
Dividend—
Analyst Ratings
3 Buy 8 Hold 1 Sell
Consensus Hold
Company Info
CEOYongfeng Zhang
Employees1,976
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2014-06-25
11570 6th Street
Rancho Cucamonga, CA 91730
US
909 980 9484
About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

Recent Insider Trades

NameTypeSharesPriceDate
PETERS WILLIAM J S-Sale 4,139 $25.00 2026-09-21
Zhou Rong M-Exempt 10,000 $13.35 2026-09-16
Zhou Rong S-Sale 10,000 $23.94 2026-09-16
Zhou Rong M-Exempt 10,000 $13.35 2026-09-16
Zhou Rong S-Sale 3,187 $23.63 2026-09-02

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms